

HAEMONETICS CORP  
Form 8-K  
July 27, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 21, 2016

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts 001-14041 04-2882273  
(State or other jurisdiction (Commission (I.R.S. Employer  
of incorporation) File Number) Identification No.)

400 Wood Road  
Braintree Massachusetts 02184  
(Address of principal executive offices) (Zip Code)  
Registrant's telephone number, including area code 781-848-7100  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



ITEM 5.07 Submission of Matters to a Vote of Security Holders.

Haemonetics Corporation's Annual Meeting of Stockholders was held on July 21, 2016. At the Meeting:

1. Susan Bartlett Foote, Pedro P. Granadillo and Mark W. Kroll, PhD were elected to serve as directors of Haemonetics Corporation;
2. An advisory vote regarding the compensation of our named executive officers was approved;
3. The Amendment to Haemonetics Corporation's 2007 Employee Stock Purchase Plan was approved;
4. The adoption of Haemonetics Corporation's Worldwide Executive Bonus Plan was approved; and
5. The selection of Ernst & Young LLP to serve as the independent registered public accounting firm of Haemonetics Corporation for fiscal year 2017 was ratified.

Below are the number of votes cast for or against, the number of abstentions, the number of votes withheld and the number of broker non-votes:

1. Election of Directors:

| Director             | Votes For  | Withheld  | Non-Vote  |
|----------------------|------------|-----------|-----------|
| Susan Bartlett Foote | 43,465,094 | 3,211,945 | 1,622,173 |
| Pedro P. Granadillo  | 43,462,839 | 3,214,200 | 1,622,173 |
| Mark W. Kroll, PhD   | 43,626,353 | 3,050,686 | 1,622,173 |

2. Executive Compensation:

| Votes For  | Votes Against | Abstain | Non-Vote  |
|------------|---------------|---------|-----------|
| 46,366,803 | 287,590       | 22,646  | 1,622,173 |

3. Approval of Amendment to 2007 Employee Stock Purchase Plan:

| Votes For  | Votes Against | Abstain | Non-Vote  |
|------------|---------------|---------|-----------|
| 45,619,183 | 1,041,137     | 16,719  | 1,622,173 |

4. Adoption of Worldwide Executive Bonus Plan:

| Votes For  | Votes Against | Abstain | Non-Vote  |
|------------|---------------|---------|-----------|
| 45,834,334 | 822,157       | 20,548  | 1,622,173 |

5. Ratification of Auditors:

| Votes For  | Votes Against | Abstain | Non-Vote |
|------------|---------------|---------|----------|
| 48,067,800 | 190,878       | 40,534  | —        |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION  
(Registrant)

Date: July 27, 2016 By: /s/ Sandra Jesse  
Sandra Jesse, Executive Vice President and  
Chief Legal Officer